NDT Advance Access originally published online on December 22, 2004
Nephrology Dialysis Transplantation 2005 20(2):413-418; doi:10.1093/ndt/gfh641
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant Vol. 20 No. 2 © ERA–EDTA 2004; all rights reserved
Original Article
Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients
Department of Medicine, Section of Nephrology, Rikshospitalet University Hospital, Oslo, Norway
Correspondence and offprint requests to: Monica Hagen Voytovich, Department of Medicine, Section of Nephrology, Laboratory for Renal Physiology, Rikshospitalet University Hospital, 0027 Oslo, Norway. Email: monica.hagen{at}rikshospitalet.no
Background. Insulin resistance (IR) contributes to the development of glucose intolerance (post-transplant diabetes mellitus or impaired glucose tolerance) following renal transplantation. Furthermore, endothelial dysfunction (ED) is associated with IR. Glucose intolerance, IR and ED are all independent risk factors for cardiovascular disease. Therefore, treatment with insulin sensitizers may benefit glucose-intolerant renal transplant recipients. The main objectives of the present study were to investigate the effect of 4 weeks’ treatment with the PPAR-
agonist rosiglitazone on insulin sensitivity, plasma glucose and endothelial function in renal transplant recipients with glucose intolerance. Safety parameters were also addressed.
Methods. A total of 10 glucose-intolerant renal transplant recipients were treated with rosiglitazone (initially 4 mg/day increasing to 8 mg/day after 1 week). A hyperinsulinaemic euglycaemic glucose clamp, an oral glucose tolerance test and endothelial function assessment with laser Doppler flowmetry were performed both at baseline and at follow-up.
Results. Treatment with rosiglitazone was followed by a significantly improved mean glucose disposal rate (from 6.5 to 9.1 g/kg/min; P = 0.02) and a significant decline in fasting and 2 h plasma glucose (from 6.4 to 5.8 mmol/l, P = 0.01 and from 14.2 to 10.6 mmol/l, P = 0.03, respectively). Furthermore, a significant improvement in endothelial function was demonstrated (AUCACh; from 389 to 832 AU · min, P = 0.04). No serious adverse events or hypoglycaemic episodes were observed.
Conclusions. Four weeks’ treatment with rosiglitazone was associated with increased insulin sensitivity, lowered fasting and 2 h plasma glucose and improved endothelial function in renal transplant recipients with glucose intolerance. The drug was well tolerated and may be a good alternative for treating these patients.
Keywords: endothelium; glucose intolerance; insulin resistance; renal transplantation; thiazolidinediones
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J. Han, K. Y. Hur, Y. S. Kim, E. S. Kang, S. I. Kim, M. S. Kim, J. Y. Kwak, D. J. Kim, S. H. Choi, B. S. Cha, et al. Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients Nephrol. Dial. Transplant., October 28, 2009; (2009) gfp567v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhao, S. G. Thacker, J. B. Hodgin, H. Zhang, J. H. Wang, J. L. Park, A. Randolph, E. C. Somers, S. Pennathur, M. Kretzler, et al. The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus J. Immunol., August 15, 2009; 183(4): 2729 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Iglesias and J. J Diez Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ergun and K. Keven Short-term rosiglitazone treatment in renal transplant recipients Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1511 - 1512. [Full Text] [PDF]
|
|